1. Home
  2. PRAX vs CFLT Comparison

PRAX vs CFLT Comparison

Compare PRAX & CFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$309.41

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Logo Confluent Inc.

CFLT

Confluent Inc.

N/A

Current Price

$30.73

Market Cap

7.7B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
PRAX
CFLT
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
7.7B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PRAX
CFLT
Price
$309.41
$30.73
Analyst Decision
Strong Buy
Hold
Analyst Count
15
28
Target Price
$572.13
$28.73
AVG Volume (30 Days)
328.9K
7.9M
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.63
EPS
N/A
N/A
Revenue
N/A
$1,166,748,000.00
Revenue This Year
N/A
$18.71
Revenue Next Year
$6,395.88
$16.90
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.08
52 Week Low
$26.70
$15.64
52 Week High
$354.87
$30.81

Technical Indicators

Market Signals
Indicator
PRAX
CFLT
Relative Strength Index (RSI) 48.21 61.56
Support Level $290.36 $30.60
Resistance Level $322.32 $30.79
Average True Range (ATR) 16.44 0.07
MACD -4.21 -0.03
Stochastic Oscillator 38.39 53.49

Price Performance

Historical Comparison
PRAX
CFLT

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About CFLT Confluent Inc.

Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.

Share on Social Networks: